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Background: The introduction of two-view mammography at incident (subsequent) screens in the National Health Service Breast
Screening Programme (NHSBSP) has led to an increased number of cancers detected at screen. However, the effect of two-view
mammography on interval cancer rates has yet to be assessed.
Methods: Routine screening and interval cancer data were collated from all screening programmes in the United Kingdom for
women aged 50–64, screened between 1 April 2003 and 31 March 2005. Interval cancer rates were compared based on whether
two-view mammography was in use at the last routine screen.
Results: The reduction in interval cancers following screening using two-view mammography compared with one view was 0.68
per 1 000 women screened. Overall, this suggests the introduction of two-view mammography at incident screen was
accompanied by a 15–20% reduction in interval cancer rates in the NHSBSP.
Conclusion: The introduction of two-view mammography at incident screens is associated with a reduction in incidence of interval
cancers. This is consistent with previous publications on a contemporaneous increase in screen-detected cancers. The results
provide further evidence of the benefit of the use of two-view mammography at incident screens.
Mammography using two views (craniocaudal in addition to the
standard mediolateral oblique view) became standard practice in
the National Health Service Breast Screening Programme
(NHSBSP) at prevalent (first) screens in 1995, with single-view
mammography used at incident (second and subsequent) screens.
This followed the UKCCCR randomised controlled trial comparing
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the cancer detection rate achieved when using one vs two-view
mammography during routine breast screening. Results showed a
24% increase in cancer detection with two-view mammography
(Wald et al, 1995).
Further research was undertaken, including a number of
observational studies, which found that programmes using two-
view mammography saw an 8.9% increase in sensitivity (true
cancer detection) for invasive cancer detection compared with
those using a single view only (Blanks et al, 1998). This led to the
decision that two-view mammography would be undertaken at all
incident screens as well as prevalent screens. The aim was for all
units in the United Kingdom to be using two-view mammography
at all screening rounds by December 2003 (Patnick, 2004) but in
practice, only 81% of units (74 out of 91 units) had achieved this
target. All screening units in England, Wales and Northern Ireland
were using two-view mammography at incident screens by 1
December 2004. The programme in Scotland adopted two-view
mammography in 2008 (NHS Scotland, 2008). It should be noted
that screening units in Northern Ireland used two-view mammo-
graphy at both prevalent and incident screens when the breast
screening programme was introduced in 1989.
Assessment of the impact of the introduction of two-view vs
one-view mammography has been carried out in relation to screen-
detected cancer and recall rates. Blanks et al (2005) found the
overall rate of invasive and in situ cancers detected at screen
increased by 0.65 per 1 000 women screened following the
introduction of two-view mammography with recall rates falling
by 0.27 per 1 000 women screened .To date, there has been no
assessment on the impact of the introduction of two views on
interval cancer rates in the UK screening programme; therefore,
this is what we explore in this study. We focus on the UK breast
screening programme as the screening regimes in other countries
differ to that in the United Kingdom. In particular, the interval
between routine screening episodes varies; in the United Kingdom,
it is 36 months whereas many other European countries with
national screening programmes have a screening interval of 24
months (Giordano et al, 2012) and thus, it would be difficult to
compare changes in interval cancer rates. Also, we were
particularly keen to assess whether the recent policy change in
the United Kingdom, in relation to the use of two-view
mammography at incident screens, has been of equal benefit for
interval cancer rates as it has been for screen-detected cancer rates.
Interval cancers are those that occur symptomatically in the
interval between routine screening episodes. These can be cancers
which were missed by screening, cancers which became screen
detectable after the screen and then became symptomatic, and
cancers not detectable by mammography (Warren and Duffy,
2000). Interval cancer rates provide a good indicator of the
performance of a screening programme; therefore, assessment of
the change in interval cancer rates following the introduction of
two-view mammography is of interest.
MATERIALS AND METHODS
The NHSBSP currently invites women aged 50–70 to attend breast
screening every 3 years. Screening years, and subsequent reporting,
run from 1st April to 31st March the following year. Expansion of
the age range to 47–73 is being introduced, in a randomised
fashion, to enable full evaluation of the benefit of expanding the
screening age. We collated annual screening and interval cancer
data for all UK breast screening units for the screening years 2003/
04 and 2004/05 from the NHS Information Centre and the Breast
Screening Quality Assurance Reference Centres (QARCs), respec-
tively. Accurate assessment of interval cancer rates is often
hampered by the poor availability of necessary data. The NHSBSP,
however, has a rigorous system in place to ensure all screening and
interval cancer data are correctly identified and recorded. Cancer
registries are responsible for the identification of all breast cancers
diagnosed in their catchment area, including interval cancers. Data
are then collated on a regional level by QARCs, who assign a
screening history to each case of breast cancer diagnosed in women
eligible for screening, from which the cancer status can be
identified. The QARCs assess these data against numerous quality
indictors to ensure ascertainment is good before being made
available for analysis (NHS Breast Screening Programme, 2006).
This is a process that can take some time, particularly in the
identification of interval cancers, as they can occur up to 3 years
after a women’s previous screen. The most recent data available for
analysis, during which both one- and two-view mammography was
in use, were for screening years 2003/04 and 2004/05. Also, over
50% of screening units introduced two-view mammography at
incident screen in screening year 2002/03; therefore, any analysis
undertaken prior to 2003/04 would not have had a sufficient
number of units which had fully implemented two-view mammo-
graphy at incident screen for a complete screening year.
Only interval cancers occurring within 36 months of a woman’s
last negative screen were included, in line with the NHSBSP
screening guidelines for analysing interval cancers.
Only women aged 50–64 at last screen were included in the
analysis as not all units had extended the screening age to 70 years
during the study period. Data relating to routine screening were
available for all 91 screening units in the United Kingdom for both
screening years and included details of the number of women
screened and the number of cancers detected. Interval cancer data
were available for all screening units for both screening years, apart
from the six screening units in Scotland, who were only able to
provide data for screening year 2003/04.
As two-view mammography for incident screens was in the
process of being introduced during our study period, we
categorised units as follows:
 Full two view: the screening unit carried out two-view
mammography for the whole screening year of interest;
 Partial two view: the screening unit introduced two-view
mammography at some stage during the screening year of
interest;
 One view only: the screening unit carried out one-view
mammography only during the screening year of interest.
Interval cancers were defined as cancers diagnosed following a
normal screening result during the interval beginning with the
closure of the previous NHS screening episode and ending when
the next screening episode was due to commence (NHS Breast
Screening Programme, 2006). The dates to be used for the
screening episodes were the date when the last screening
mammogram was taken and the date of the next routine screening
appointment, where this was less than 36 months. If the next
appointment was more than 36 months after the last mammogram,
only interval cancers up to 36 months after the latter were
included. The way in which round length is defined means that the
achievement of the national standard is not affected by women
choosing to alter their screening appointment – a woman’s round
length is determined by the date of first offered appointment
(DOFOA) (NHS Breast Screening Programme, 2008). A screening
episode is closed when the screening outcome is known or 180
days after DOFOA in the case of non-attenders.
The aim of this analysis was to assess the effect of the
introduction of two-view mammography on interval cancer rates
in the NHSBSP. Confidentiality regulations restricted the avail-
ability of individual data, so we were unable to conduct analyses on
a per-patient level. We calculated the rates of interval cancers per
1 000 women screened by the two-view mammography status of
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the unit as defined above. We assessed the rates of invasive interval
cancers only and of all interval cancers; and for each screening year
separately and the two screening years combined. Poisson
regression was used to assess whether the rates varied by two-
view status. Analyses were performed using STATA Version 11.2
(College Station, TX, USA; Stata Corp, 2009).
As interval length, that is, the length of time elapsing between
two consecutive screens, varied between units, we repeated the
analysis restricting it to interval cancers that occurred within
24 months following a negative screen.
Where regional boundaries changed during the period under
scrutiny, the configuration of regions and responsibilities for
screening units was taken to be that which existed in screening year
2009/10, when the interval cancer data were first compiled. Five
pairs of screening units merged prior to this but as the introduction
of two-view mammography occurred in the same screening year
for each merged pair, the change in configuration will not have had
an impact on the results of this study. One new screening unit was
opened in the South West region during screening year 2004/05.
This unit was excluded. Therefore, data from 91 screening units in
the United Kingdom were included in the study.
RESULTS
A total of 1 400 613 women were screened across 91 screening units
in 2003/04, giving an average of 15 391 women screened per unit
(range 3 835–45 632). A total of 9 957 cancers were detected as
a result of screening (unit range 22–309) giving an average rate
of 7.11 cancers detected per 1 000 women screened. As data
for Scotland were unavailable for screening year 2004/05, data
on 1 278 989 women screened across 85 units (unit range
3 979–33 521) were available for analysis. This resulted in
9 192 cancers being detected (unit range 33–251) leading to an
average rate of 7.19 cancers detected per 1 000 women screened.
A total of 4 518 interval cancers were identified following screens in
2003/04 and 3 915 following screens in 2004/05, of which 4 212
(93.2%) and 3 665 (93.6%) respectively, were invasive cancers.
Table 1 shows the number of units by two-view mammography
status for each screening year. In 2003/04, 70.3% units had fully
implemented two-view mammography; this had risen to 87.9%
in 2004/05.
The interval cancer rate decreased upon the implementation of
two-view mammography in screening year 2003/04 (Table 2).
There was a 17% reduction (RR: 0.83 (95% CI 0.77–0.90,
Po0.001)) in interval cancers occurring following screening using
two-view mammography compared with single-view mammography.
A slightly smaller but significant reduction was also seen when
comparing interval cancer rates in units which introduced two
views at some stage during the screening year compared with those
units that used one-view mammography only (RR: 0.86 (95% CI
0.78–0.95, P¼ 0.004)).
By 2004/05, all screening units had introduced two-view
mammography either before the start of, or at some stage during,
the screening year. There was a significant reduction in interval
cancers of 13% (RR: 0.87 (95% CI 0.76–0.99, P¼ 0.035)) in units
which used two-view mammography throughout the screening
year compared with units who introduced it part way through.
Combining the data from both screening years produced similar
results to those seen when analysing 2003/04 data only. There was
an 18% reduction (RR: 0.82 (95% CI 0.76–0.88, Po0.001)) in
interval cancers occurring following a screen using two-view
mammography for the whole screening period compared with
units which used single view only.
We repeated the analysis to assess the effect of the introduction
of two-view mammography on invasive interval cancers only
(Table 3). There was no significant difference in interval cancer
rates following screening in year 2003/04 between units which had
introduced two-view mammography part way through the year
compared with units using one-view mammography only. There
was, however, a 10% reduction (RR: 0.90 (95% CI 0.83–0.98,
P¼ 0.017)) of invasive interval cancers occurring in units using
two-view mammography for the whole screening year compared
with one-view mammography only.
When analysing women screened in 2004/05, there was a 14%
reduction (RR: 0.86 (95% CI 0.75–0.98, P¼ 0.027)) in the number
of women who developed invasive interval cancers following
screening at units that had fully implemented two-view mammo-
graphy compared with units that introduced it part way through
the year. This is similar to the reduction seen for all interval
cancers.
For both screening years combined, there was no significant
difference in interval cancer rates between units that used one-view
mammography only and units that introduced two-view mammo-
graphy part way through the screening year. However, there was a
significant 12% reduction (RR: 0.88 (95% CI 0.81–0.96, P¼ 0.003))
in invasive interval cancer rates for women screened at units using
two-view mammography compared with those using one-view
mammography only.
Repeating the analysis restricting the diagnosis of interval cancer
to within 24 months following a negative routine screen produced
similar results to those shown in Tables 2 and 3. However,
Table 1. Two-view mammography status of screening units by screening
year
Mammography Status
1 April 2003 to
31 March 2004
1 April 2004 to
31 March 2005
One view only 11 6a
Partial two view 16 5
Full two view 64 80
aScottish units for whom we do not have interval cancer data following screening year
2004/05.

















1 April 2003 to 31 March 2004
One view only 195 224 732 3.75 Baseline
Partial two view 249 865 808 3.23 0.86 (0.78–0.95)
Full two view 955 524 2 978 3.12 0.83 (0.77–0.90)
1 April 2004 to 31 March 2005
One view only N/Aa N/Aa N/Aa N/Aa
Partial two view 68 379 239 3.5 Baseline
Full two view 1 210 610 3 676 3.04 0.87 (0.76–0.99)
1 April 2003 to 31 March 2005
One view only 195 224 732 3.75 Baseline
Partial two view 318 244 1 047 3.29 0.88 (0.80–0.96)
Full two view 2 166 134 6 654 3.07 0.82 (0.76–0.88)
Abbreviation: CI¼ confidence interval.
aOnly six units in Scotland used one view only in 2004/05, and for these units data were not
available.
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B44% of interval cancers were diagnosed in the third year
following a negative routine screen in both screening years 2003/04
and 2004/05 (1 958/4 518 and 1 728/3 915, respectively) and thus
the reduction in sample size led to wider confidence intervals.
Results are shown in Tables 4 and 5.
DISCUSSION
The introduction of two-view mammography has led to a
reduction in interval cancers occurring following a negative
routine screen in comparison with one-view mammography. This
is consistent with a corresponding rise in the number of cancers
detected at screening (Blanks et al, 2005). The reduction in all
interval cancer rates associated with two-view mammography was
0.68 per 1 000 screened (Table 2, both screening years combined),
very close to the 0.65 per 1 000 increase from 5.87 to 6.52 in screen-
detection rates in the Study Group of Blanks and colleagues
(Blanks et al, 2005). This indicates that the increase in screen-
detection rates with two-view mammography is not likely to be
attributable to overdiagnosis. Overdiagnosis is the detection, by
screening, of cancers that would never have come to clinical
attention had screening not taken place (Duffy, 2005). If the
decrease in interval cancer rates was smaller than the increase in
screen-detected cancers, then the excess in screen-detected cancers
following the introduction of two-view mammography may be as a
result of overdiagnosis. However, given that the increase in screen-
detected cancers is consistent with the decrease in interval cancers,
the number of additional screen-detected cancers using two-view
mammography, which are attributable to overdiagnosis, is likely to
be minimal. There is always room for argument about over-
diagnosis, as the phenomenon cannot be observed at an individual
level. However, the results here suggest that at least there is no
cause for alarm in this respect over the change to two-view
mammography. Further observation of both screen-detected and
interval cancer rates in the future will be useful in terms of likely
overdiagnosis due to other innovations such as digital
mammography.
A study in France found a larger proportional effect of changing
from single- to two-view mammography on two-year
interval cancer rates, finding a reduction of more than 30%
(Seigneurin et al, 2009). However, this study compared universal
two-view with universal single view rather than a change for
incident screens only, as in our case.
Interval cancers tend to have poorer stage and poorer prognosis
as one would expect (Biesheuvel et al, 2011; Nagtegaal et al, 2011;
Domingo et al, 2013). Interval cancer rates are in the order of 2–3
per 1 000 screened in the UK programme (Bennett et al, 2011).
This is somewhat less than 50% of tumours diagnosed in women
attending the programme, but still a non-negligible number.
Results from other countries with more frequent screening are
consistent with this (Ciatto et al, 2011). Clearly, reduction in
Table 4. Interval cancer rates by screening year for cancers diagnosed

















1 April 2003 to 31 March 2004
One view only 195 224 399 2.04 Baseline
Partial two view 249 865 465 1.86 0.91 (0.80–1.04)
Full two view 955 524 1 696 1.78 0.87 (0.78–0.97)
1 April 2004 to 31 March 2005
One view only N/Aa N/Aa N/Aa N/Aa
Partial two view 68 379 127 1.89 Baseline
Full two view 1 210 610 2 060 1.7 0.92 (0.77–1.10)
1 April 2003 to 31 March 2005
One view only 195 224 399 2.04 Baseline
Partial two view 318 244 592 1.86 0.91 (0.80–1.03)
Full two view 2 166 134 3 756 1.73 0.85 (0.77–0.94)
Abbreviation: CI¼ confidence interval.
aOnly six units in Scotland used one view only in 2004/05, and for these units data were not
available.
Table 5. Invasive interval cancer rates by screening year for cancers

















1 April 2003 to 31 March 2004
One view only 195 224 355 1.82 Baseline
Partial two view 249 865 435 1.74 0.96 (0.83–1.10)
Full two view 955 524 1 589 1.66 0.91 (0.82–1.03)
1 April 2004 to 31 March 2005
One view only N/Aa N/Aa N/Aa N/Aa
Partial two view 68 379 120 1.76 Baseline
Full two view 1 210 610 1 914 1.58 0.90 (0.75–1.08)
1 April 2003 to 31 March 2005
One view only 195 224 355 1.82 Baseline
Partial two view 318 244 555 1.74 0.96 (0.84–1.10)
Full two view 2 166 134 3 503 1.62 0.89 (0.80–1.00)
Abbreviation: CI¼ confidence interval.
aOnly six units in Scotland used one view only in 2004/05, and for these units data were not
available.

















1 April 2003 to 31 March 2004
One view only 195 224 638 3.27 Baseline
Partial two view 249 865 761 3.05 0.93 (0.84–1.04)
Full two view 955 524 2 813 2.94 0.90 (0.83–0.98)
1 April 2004 to 31 March 2005
One view only N/Aa N/Aa N/Aa N/Aa
Partial two view 68 379 226 3.31 Baseline
Full two view 1 210 610 3 439 2.84 0.86 (0.75–0.98)
1 April 2003 to 31 March 2005
One view only 195 224 638 3.27 Baseline
Partial two view 318 244 987 3.10 0.95 (0.86–1.05)
Full two view 2 166 134 6 252 2.89 0.88 (0.81–0.96)
Abbreviations: CI¼ confidence interval.
aOnly six units in Scotland used one view only in 2004/05, and for these units data were not
available.
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interval cancer incidence is a suitable target for screening
programmes.
The benefit seen following the introduction of two-view
mammography was larger when analysing all interval cancers
than when restricting to invasive interval cancers only (Tables 2
and 3). This was not simply a feature of greater statistical power
with larger numbers, which would lead to smaller standard errors
(s.e.) and thus more precise estimates of rates. The absolute and
relative reductions in interval cancer rates were also larger when
non-invasive cancers are included. This is consistent with the
observation that compared with contemporaneous changes in a
reference group not using two-view mammography, the propor-
tional increase in detection of in situ tumours with two-view
mammography was greater than for invasive (Blanks et al, 2005).
This study uses data on interval cancers from almost all units in
the United Kingdom over a 2-year period and thus benefits from
large number of women screened and subsequent interval cancers
recorded. Also, as the breast screening programme operates on a
national level and has a rigorous call/recall system in place, we can
be confident that the interval cancer rates calculated accurately
reflect the true rates occurring in the population eligible for
screening. Many other countries do not have similarly organised
population-based screening programmes in place, thus making it
difficult to clearly distinguish interval cancers from those detected
at screening or in non-attenders.
Assessment of potential confounding factors, such as age at
screening, was not possible due to confidentiality restrictions
meaning we were unable to obtain data at an individual patient
level. Comparison of interval cancer rates by unit may therefore have
introduced potential confounders at a geographical level, such as
variation in underlying incidence or the recording of interval cancers,
or the possibility that units which were quicker to change to two-
view mammography are more effective in identifying interval cancers
a priori than those still using one view. However, the NHSBSP has a
robust quality assurance system in place to ensure that all cancers
that occur in women eligible for screening are identified and
classified appropriately as well as having strict screening guidelines in
place to ensure that all women receive the same high quality level of
care when attending screening. Incidence does vary geographically
within the United Kingdom, but it is uniformly high. In any case, as
interval cancers following subsequent years of screening become
available, it will be possible to track interval cancer rates over time by
individual screening unit, and assess whether changes in rates are
consistent with the time of the move to two-view mammography. By
considering changes within rather than between units, geographical/
unit level confounders can be controlled for.
In conclusion, this study found that the introduction of two-
view mammography at incident screens was accompanied by a
15–20% reduction in interval cancer rates in the NHSBSP. This,
therefore, supports the decision at national level to change to two-
view mammography at incident screens. In Europe, there are a
number of programmes which still use single-view mammography
at incident screens (Giordano et al, 2012). These results will have
relevance for those programmes.
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